Andy Qingan Yuan
Andy Qingan Yuan has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Anis Khan
Department of Clinical Pharmacology and Drug Metabolism and Pharmacokinetics, MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878, USA
1 shared publicationBettina W. M. Richter
Department of Infectious Disease, MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878, USA
1 shared publicationBrian Moldt
Department of Infectious Disease, MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878, USA
1 shared publication- Catherine Svabek
Department of Infectious Disease, MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878, USA
1 shared publication - Daniel Wrapp
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, USA
1 shared publication Hong Fang
Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
1 shared publication
Latest Publications
- Open Access
- 24 August 2021
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 13 (9) , e14291
The state of the art of bispecific antibodies for treating human malignancies
Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer. Here, we provide an overview of various types of bsAbs in clinical studies and discuss their targets, safety profiles, and efficacy. We also highlight the current challenges, potential solutions, and future directions of bsAb development for cancer treatment.
- 24 August 2021
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 13 (9) , e14291
Open AccessThe state of the art of bispecific antibodies for treating human malignancies
Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer. Here, we provide an overview of various types of bsAbs in clinical studies and discuss their targets, safety profiles, and efficacy. We also highlight the current challenges, potential solutions, and future directions of bsAb development for cancer treatment.
- Top Cited Papers
- 3 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (388)
A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Development of a highly potent anti-RSV monoclonal antibody with extended half-life intended to be used as RSV prophylaxis for all infants.
- 3 May 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (388)
Top Cited PapersA highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants
Development of a highly potent anti-RSV monoclonal antibody with extended half-life intended to be used as RSV prophylaxis for all infants.